---
title: "HL CORP released its 2024 annual performance, with a net loss attributable to the parent company of 18.93 million yuan, turning from profit to loss year-on-year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237008180.md"
description: "According to the Zhitong Finance APP, HL CORP disclosed its 2024 annual report. During the reporting period, the company achieved revenue of 1.191 billion yuan, a year-on-year increase of 23.58%; the net profit attributable to the parent company was a loss of 18.93 million yuan, turning from profit to loss compared to the previous year; the net profit excluding non-recurring gains and losses was a loss of 23.65 million yuan, also turning from profit to loss compared to the previous year; the basic earnings per share were -0.052 yuan"
datetime: "2025-04-22T15:07:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237008180.md)
  - [en](https://longbridge.com/en/news/237008180.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237008180.md)
generator: "portal-rs"
---

# HL CORP released its 2024 annual performance, with a net loss attributable to the parent company of 18.93 million yuan, turning from profit to loss year-on-year

According to the Zhitong Finance APP, HL CORP (002105.SZ) disclosed its annual report for 2024. During the reporting period, the company achieved revenue of 1.191 billion yuan, a year-on-year increase of 23.58%; the net profit attributable to shareholders was a loss of 18.93 million yuan, turning from profit to loss year-on-year; the net profit excluding non-recurring gains and losses was a loss of 23.65 million yuan, also turning from profit to loss year-on-year; the basic earnings per share were -0.052 yuan

### Related Stocks

- [002105.CN](https://longbridge.com/en/quote/002105.CN.md)

## Related News & Research

- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [CrossCountry cancels almost all trains after power cut](https://longbridge.com/en/news/296698005.md)
- [NIO: Pre-feasibility study completed; improved earnings, but external funding needed for growth](https://longbridge.com/en/news/296445284.md)
- [Vivmark Residential Insiders Sold Shares Worth Over $2.1M](https://longbridge.com/en/news/296416547.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**